NCT06788080View on ClinicalTrials.gov

Optimization of Biotinylation Protocol for Studies of Red Blood Cell Survival and Function After Transfusion

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 7, 2024

Primary Completion Date

November 4, 2024

Study Completion Date

November 4, 2024

Conditions
Measuring Red Blood Cell Survival After Transfusion
Interventions
DRUG

BioRBC

Autologous biotin-labeled RBCs will be transfused to study participants

Trial Locations (2)

80045

Anschutz Medical Center, Aurora

80230

Vitalant Research Institute, Denver

All Listed Sponsors
collaborator

University of Colorado, Denver

OTHER

lead

Vitalant Research Institute

OTHER

NCT06788080 - Optimization of Biotinylation Protocol for Studies of Red Blood Cell Survival and Function After Transfusion | Biotech Hunter | Biotech Hunter